Accelerated Early Phase Decision-Making – Insider Insights to Speed Development

Access insider insights from combined perspectives of clinical pharmacology, global regulatory considerations, and private equity investors on accelerating early development timelines to go/no go decisions and early proof of concept, without shortcuts. Parexel’s early phase team and EQT LifeSciences share best practices for combining sequential early phase studies into a single protocol.

Return to Insights Center

Related Insights

Related Insights

Video

Overcoming asset transfer challenges during a merger and acquisition (M&A)

Oct 20, 2021

Blog

Focusing on value drivers to reduce risk in early-stage drug development

Jan 6, 2025

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Blog

Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development

Jan 22, 2025

Blog

Overcoming risks in Phase 3 trials to accelerate time to market

Jan 22, 2025

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Show more